BiomX (PHGE) Operating Expenses (2018 - 2026)
BiomX (PHGE) posted Operating Expenses of $1.3 million for Q1 2026, down 94.09% sequentially from $21.9 million in Q4 2025, and down 83.29% YoY from $7.8 million in Q1 2025.
BiomX (PHGE) Operating Expenses (2018 - 2026) Analysis & Trends
BiomX has reported Operating Expenses for 9 years, with the latest figure at $1.3 million in Q1 2026.
- Quarterly Operating Expenses fell 83.29% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.8 million (up 17.83% YoY) and the FY2025 annual result came in at $30.9 million, down 17.5% from the prior year.
- Operating Expenses fell to $1.3 million in Q1 2026 per PHGE's latest filing, from $21.9 million in the prior quarter.
- Over five years, Operating Expenses peaked at $21.9 million in Q4 2025 and troughed at -$10.3 million in Q4 2023.
- A 5-year average of $5.2 million and a median of $6.8 million in 2022 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses tumbled 298.88% in 2023, then soared 191.26% in 2024.
- Over 5 years, Operating Expenses stood at $5.2 million in 2022, then sank by 298.88% to -$10.3 million in 2023, then jumped by 191.26% to $9.4 million in 2024, then surged by 133.39% to $21.9 million in 2025, then plunged by 94.09% to $1.3 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $1.3 million, $21.9 million, and -$1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | BiomX | 361,408.40 | -806,591.60 | - | 1.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.30 Mn |
| Dec 31, 2025 | 21.94 Mn |
| Sep 30, 2025 | -1.84 Mn |
| Jun 30, 2025 | 7.43 Mn |
| Mar 31, 2025 | 7.76 Mn |
| Dec 31, 2024 | 9.40 Mn |
| Sep 30, 2024 | -2.41 Mn |
| Jun 30, 2024 | 9.73 Mn |
| Dec 31, 2023 | -10.30 Mn |
| Sep 30, 2023 | 7.80 Mn |
| Jun 30, 2023 | 6.26 Mn |
| Mar 31, 2023 | 565,000.00 |
| Dec 31, 2022 | 5.18 Mn |
| Sep 30, 2022 | 6.43 Mn |
| Jun 30, 2022 | 7.14 Mn |
| Mar 31, 2022 | 7.41 Mn |
| Dec 31, 2021 | 9.41 Mn |
| Sep 30, 2021 | 9.90 Mn |
| Jun 30, 2021 | 6.92 Mn |
| Mar 31, 2021 | 8.36 Mn |